Labels for oral contraceptives that contain drospirenone will now note that studies have shown as much as a threefold increase in risk of blood clots compared with other birth control pills, the FDA said. Following a safety review that began last May, the agency "has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills." The label changes apply to nine brand-name contraceptives -- Beyaz, Gianvi, Loryna, Ocella, Safyral, Syeda, Yasmin, Yaz, and Zarah -- and two generic formulations, all of which include 3 mg of drospirenone and either 0.02 or 0.03 mg of ethinyl estradiol.